Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study

BACKGROUND: There is a paucity of studies evaluating perioperative systemic chemotherapy in conjunction with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer peritoneal metastases (CRCPM). The aim was to evaluate neoadjuvant and/or...

Descripción completa

Detalles Bibliográficos
Autores principales: Cashin, Peter H., Esquivel, Jesus, Larsen, Stein G., Liauw, Winston, Alzahrani, Nayef A., Morris, David L., Kepenekian, Vahan, Sourrouille, Isabelle, Dumont, Frédéric, Tuech, Jean-Jacques, Ceribelli, Cécilia, Doussot, Beranger, Sgarbura, Olivia, Quenet, Francois, Glehen, Olivier, Fisher, Oliver M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706515/
https://www.ncbi.nlm.nih.gov/pubmed/36457647
http://dx.doi.org/10.1016/j.eclinm.2022.101746
Descripción
Sumario:BACKGROUND: There is a paucity of studies evaluating perioperative systemic chemotherapy in conjunction with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer peritoneal metastases (CRCPM). The aim was to evaluate neoadjuvant and/or adjuvant systemic therapy in CRCPM. METHODS: Patients with CRCPM from 39 treatment centres globally from January 1, 1991, to December 31, 2018, who underwent CRS+HIPEC were identified and stratified according to neoadjuvant/adjuvant use. Crude data analysis, propensity score matching (PSM) and Cox-proportional hazard modelling was performed. FINDINGS: Of 2093 patients, 1613 were included in neoadjuvant crude evaluation with 708 in the PSM cohort (354 patients/arm). In the adjuvant evaluation, 1176 patients were included in the crude cohort with 778 in the PSM cohort (389 patients/arm). The median overall survival (OS) in the PSM cohort receiving no neoadjuvant vs neoadjuvant therapy was 37.0 months (95% CI: 32.6–42.7) vs 34.7 months (95% CI: 31.2–38.8, HR 1.08 95% CI: 0.88–1.32, p = 0.46). The median OS in the PSM cohort receiving no adjuvant therapy vs adjuvant therapy was 37.0 months (95% CI: 32.9–41.8) vs 45.7 months (95% CI: 38.8–56.2, HR 0.79 95% CI: 0.64–0.97, p = 0.022). Recurrence-free survival did not differ in the neoadjuvant evaluation but differed in the adjuvant evaluation – HR 1.04 (95% CI: 0.87–1.25, p = 0.66) and 0.83 (95% CI: 0.70–0.98, p = 0.03), respectively. Multivariable Cox-proportional hazard modelling in the crude cohorts showed hazard ratio 1.08 (95% CI: 0.92–1.26, p = 0.37) for administering neoadjuvant therapy and 0.86 (95% CI: 0.72–1.03, p = 0.095) for administering adjuvant therapy. INTERPRETATION: Neoadjuvant therapy did not confer a benefit to patients undergoing CRS+HIPEC for CRCPM, whereas adjuvant therapy was associated with a benefit in this retrospective setting. FUNDING: None.

Ejemplares similares